Sheng et al. [25] suggested that overexpression of the transcriptional regulator BACH2 represses Th9 cell differentiation by suppressing IRF4 expression in SLE patients, and that it might be a potential target for SLE treatment. Here, IRF4 is linked to systemic lupus erythematosus.